2011-05-20, ACS Biomarker B.V. closes financing round and appoints new CEO.
ACS Biomarker B.V., a Dutch biotechnology company focused on the discovery, validation and commercialization of novel cardiovascular biomarkers announces the closing of a financing round. The investment….. Read more (English) Read more (Dutch)

2010-12-10, FDA goedkeuring voor ‘Maastrichtse’ biomarker Galectine-3
De Amerikaanse Registratie Autoriteit FDA (Food and Drug Administration) heeft de ‘Galectine-3 test’ goedgekeurd voor de Amerikaanse markt….. Read more

27-01-2010, BG Medicine krijgt CE-markering voor galectin-3-test.
Waltham, MA, VS - 27 januari 2010 - BG Medicine, Inc., een particuliere onderneming, gericht op het ontdekken van biomarkers en…… Read more

17-11-2009, Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform
ABBOTT PARK, Ill. and WALTHAM, Mass., Nov. 17 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker………Read more

05-02-2008, BG Medicine Acquires Exclusive Commercial Rights to Biomarker of Vascular Plaque Rupture from ACS Biomarker
BG Medicine plans to develop and commercialize diagnostic tests to aid in early diagnosis of acute cardiac and cerebral……..Read more

11-10-2007, ACS Biomarker opens office in BioPartner Center Maastricht.
ACS Biomarker b.v. develops and commercializes cardiovascular biomarkers discovered at the Cardiovascular Research Institute……… Read more